Roivant Q1 FY2027: net loss narrows 15% to -$189.8M on below-the-line factors

Filed August 6, 2026 · Period ending June 30, 2026 · Compared to 10-Q Aug 11, 2025 · ~2 min read

Key Changes

• high

  Operating loss widened 28% to $366.0M while net loss narrowed 15% to $189.8M ($0.26/share), driven by $114.6M in below-the-line improvements: non-operating/other +$55.8M, income tax +$8.6M, noncontrolling interest +$50.2M. Revenue fell 33.5% to $1.4M.

  MD&A: Operating Results verify on EDGAR →
• high

  Genevant received $771.6M from Moderna settlement in July 2026 (post-period), with up to $1.3B contingent on appeal outcome. GSL will distribute up to $188M to non-Roivant shareholders. Company accrued $22.9M in settlement-related bonuses.

  Notes: Moderna Settlement / Subsequent Events view on EDGAR →
• high

  Brepocitinib NDA for dermatomyositis under FDA review with PDUFA date in 3Q 2026; Phase 3 trial in cutaneous sarcoidosis enrolling (77% vs 0% placebo in Phase 2); Phase 2b/3 in lichen planopilaris progressing.

  MD&A: Pipeline Updates verify on EDGAR →